<code id='6A946EC116'></code><style id='6A946EC116'></style>
    • <acronym id='6A946EC116'></acronym>
      <center id='6A946EC116'><center id='6A946EC116'><tfoot id='6A946EC116'></tfoot></center><abbr id='6A946EC116'><dir id='6A946EC116'><tfoot id='6A946EC116'></tfoot><noframes id='6A946EC116'>

    • <optgroup id='6A946EC116'><strike id='6A946EC116'><sup id='6A946EC116'></sup></strike><code id='6A946EC116'></code></optgroup>
        1. <b id='6A946EC116'><label id='6A946EC116'><select id='6A946EC116'><dt id='6A946EC116'><span id='6A946EC116'></span></dt></select></label></b><u id='6A946EC116'></u>
          <i id='6A946EC116'><strike id='6A946EC116'><tt id='6A946EC116'><pre id='6A946EC116'></pre></tt></strike></i>

          hotspot

          hotspot

          author:explore    Page View:7957
          he exterior of the U.S. Capitol building is seen at sunrise
          Sarah Silbiger/Getty Images

          WASHINGTON — Panels in both the House and Senate have now passed restrictions to drug middlemen business practices, increasing the chances of those measures being included in future government spending bills.

          The bipartisan reforms to pharmacy benefit managers were among 21 bills that the House Energy & Commerce health subcommittee passed today. The policies are not identical, but at least three PBM reforms have been passed by panels in both chambers:

          advertisement

          • One that would replace PBM fees that are tied to a percentage of drug prices with flat fees
          • Another that would require Medicare to create standard performance measures on which PBMs base pharmacy payments
          • A third that would require PBMs to report a host of information, including drug costs, savings, beneficiary out-of-pocket costs, payments to pharmacies, and the amount of business directed to PBM-owned pharmacies

          The Energy & Commerce subcommittee also passed other bills that mirror legislation that Senate Finance also has passed. That includes legislation to ensure seniors pay no more for drugs than insurers, and a measure that lets insurers add less-expensive biosimilars to formularies mid-year.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          In Memoriam: Notable people who died in 2023
          In Memoriam: Notable people who died in 2023

          1:29AlanArkinattendsthe26thAnnualScreenActorsGuildAwardsatTheShrineAuditoriumonJan.19,2020inLosAngel

          read more
          The strategy behind pharma's lawsuits over drug pricing reform
          The strategy behind pharma's lawsuits over drug pricing reform

          Legalexpertsunpackedthepharmaceuticalindustry'sscattershotapproachtochallengingMedicare'snewpowerton

          read more
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more

          New guidelines on severe brain injury complicate already difficult decisions

          AdobeWhensomeonesustainsaseriousbraininjuryandisunresponsive,howsooncandoctorssaywhetherheorshehasac